Page last updated: 2024-09-05

sb 203580 and veratridine

sb 203580 has been researched along with veratridine in 1 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(veratridine)
Trials
(veratridine)
Recent Studies (post-2010) (veratridine)
3,48941,1371,755086

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kanai, T; Maruta, T; Miyazaki, S; Nemoto, T; Satoh, S; Wada, A; Yanagita, T; Yoshikawa, N1

Other Studies

1 other study(ies) available for sb 203580 and veratridine

ArticleYear
Nav1.7-Ca2+ influx-induced increased phosphorylations of extracellular signal-regulated kinase (ERK) and p38 attenuate tau phosphorylation via glycogen synthase kinase-3beta: priming of Nav1.7 gating by ERK and p38.
    European journal of pharmacology, 2010, Aug-25, Volume: 640, Issue:1-3

    Topics: Animals; Calcium; Carbazoles; Cattle; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Growth Cones; Humans; Imidazoles; Ion Channel Gating; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nicotine; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase C-alpha; Pyridines; Receptors, Nicotinic; Sodium Channels; tau Proteins; Tetrodotoxin; Time Factors; Veratridine

2010